ST Pharm Signs Supply Contract for Oligonucleotide Therapeutic APIs with US Biotech Company

Worth Approximately 82.5 Billion Won

ST Pharm announced on January 23 that it has signed a contract worth 56 million dollars (approximately 82.5 billion won) to supply active pharmaceutical ingredients (APIs) for oligonucleotide therapeutics to a global biotech company based in the United States.

Exterior view of ST Pharm Banwol Campus. ST Pharm

According to ST Pharm, the name of the client company and the product will not be disclosed due to confidentiality agreements. The contract period runs from January 22 to December 18 of this year.

The API covered by this supply contract is a treatment for severe hypertriglyceridemia. It will be used in a new drug scheduled for commercialization.

Last year, ST Pharm completed the construction of its second oligonucleotide production building and will begin full-scale operations in the second half of the year. According to the company, this facility is equipped with process stability and impurity minimization systems, enabling consistent quality from clinical to commercial production.

A representative from ST Pharm stated, "We are strengthening our capability to stably supply oligonucleotide therapeutic APIs through an integrated platform that encompasses technology, regulatory, and supply chain aspects. From the early development stage to process, analysis, and change approval, we provide a variety of services tailored to client needs."